インドネシアの体外診断市場:2027 年までの予測

出版:Market Research Future(マーケットリサーチフューチャー) 出版年月:2022年9月

Indonesia In-Vitro Diagnostics Market Research Report Forecast to 2027
インドネシアの体外診断市場調査レポート:2027 年までの予測

ページ数 82
価格
シングルユーザライセンス USD2,950
エンタープライズライセンス USD5,250
種別 英文調査報告書

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

Indonesia In-Vitro Diagnostics Market Research Report Forecast to 2027

Market OVERVIEW
In-vitro diagnostics (IVD) are medical devices, reagents, and accessories used to perform tests on samples, (e.g., blood, urine, and tissue) taken from the human body to help detect infection, diagnose a medical condition, and prevent disease. IVD plays a major role in the early diagnosis and management of diseases. The key factors that drive the Indonesia in-vitro diagnostics market are rising prevalence of chronic & infectious diseases and growing awareness of personalized medicine. However, an unfavorable reimbursement scenario is anticipated to hamper the market growth.
In-vitro diagnostics (IVDs) are non-invasive tests performed on biological samples (for example, blood, urine, or tissues) to diagnose a disease. IVDs provide valuable information on the body’s functioning and state of health. IVD is used for the diagnosis, screening, and therapeutic monitoring of diseases. IVDs have a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple self-tests, such as those for pregnancy and glucose monitoring.
The Indonesia in-vitro diagnostics market is emerging due to the high prevalence of chronic and infectious diseases, increasing adoption of point-of-care testing, and rising collaborations between private and public organizations for the development of the healthcare sector are responsible for the growth of the Indonesia in-vitro diagnostics market. However, regulatory procedures for high/moderate-complexity tests and information and interest gap between investors and developers are likely to restrain the market growth during the forecast period. The scope of the Indonesia in-vitro diagnostics market study includes market size analysis and a detailed analysis of the manufacturer’s products and service strategies.
Market Segmentation
The market has been segmented based on product & services, technology, application and end user.
The Indonesia in-vitro diagnostics market is segmented on the basis of product & services into reagents & kits, instruments, data management, and software & services. The instruments segment is further segmented into fully automated instruments and semi-automated instruments.
The Indonesia in-vitro diagnostics market is segmented on the basis of technology into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hemostasis, hematology, and others. The others segment includes microbiology and tissue diagnostics.
Based on application, the Indonesia in-vitro diagnostics market is bifurcated into infectious diseases oncology, cardiology, autoimmune diseases, nephrology, diabetes, HIV-AIDS, drug testing, and pharmacogenomics.
Based on end user, the Indonesia in-vitro diagnostics market is segmented into hospitals, laboratories, point-of-care testing, academic institutes, and others.
Major Players
The key players of the Indonesia in-vitro diagnostics market are BD, Bio-rad Laboratories, Thermo Fisher Scientific, Biomeruix SA, and Danaher Corporation.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.


目次

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
4.2.2 INCREASING ADOPTION OF POINT-OF-CARE TESTING
4.2.3 RISING COLLABORATIONS BETWEEN PRIVATE AND PUBLIC ORGANIZATIONS FOR THE DEVELOPMENT OF THE HEALTHCARE SECTOR
4.3 RESTRAINTS
4.3.1 REGULATORY PROCEDURES FOR HIGH/MODERATE-COMPLEXITY TESTS
4.3.2 INFORMATION AND INTEREST GAP BETWEEN INVESTORS AND DEVELOPERS
4.4 OPPORTUNITY
4.4.1 GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON MARKET
5.3.3 IMPACT ON R&D
6 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES
6.1 OVERVIEW
6.2 REAGENTS & KITS
6.3 INSTRUMENTS
6.4 DATA MANAGEMENT
6.5 SOFTWARE & SERVICES
7 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 IMMUNOASSAY/IMMUNOCHEMISTRY
7.3 CLINICAL CHEMISTRY
7.4 MOLECULAR DIAGNOSTICS
7.5 HEMOSTASIS
7.6 HEMATOLOGY
7.7 OTHERS
8 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 INFECTIOUS DISEASES
8.3 DIABETES
8.4 ONCOLOGY
8.5 CARDIOLOGY
8.6 AUTOIMMUNE DISEASES
8.7 HIV/AIDS
8.8 DRUG TESTING
8.9 NEPHROLOGY
8.10 PHARMACOGENOMICS
8.11 OTHERS
9 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 LABORATORIES
9.4 POINT-OF-CARE TESTING
9.5 ACADEMIC INSTITUTES
9.6 OTHERS
10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW
10.2 MAJOR PLAYERS IN THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
10.3 COMPETITIVE BENCHMARKING
10.4 MAJOR PLAYERS FINANCIAL MATRIX
10.4.1 REVENUE OF MAJOR PLAYERS, 2020
10.4.2 R&D EXPENDITURE, 2020
11 COMPANY PROFILES
11.1 F. HOFFMANN-LA ROCHE LTD
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS/SERVICES OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 SYSMEX CORPORATION
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS/SERVICES OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIES
11.3 DANAHER CORPORATION
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS/SERVICES OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 BIO-RAD LABORATORIES, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS/SERVICES OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 BIOMÉRIEUX SA
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS/SERVICES OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 BECTON, DICKINSON AND COMPANY
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS/SERVICES OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 SIEMENS
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS/SERVICES OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 THERMO FISHER SCIENTIFIC, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 QIAGEN
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS/SERVICES OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 AGILENT TECHNOLOGIES
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS/SERVICES OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2018–2027 (USD MILLION)
TABLE 4 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY REAGENTS & KITS, 2018–2027 (USD MILLION)
TABLE 5 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY INSTRUMENTS, 2018–2027 (USD MILLION)
TABLE 6 INDONESIA IN-VITRO DIAGNOSTICS MARKET, FOR INSTRUMENTS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 7 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DATA MANAGEMENT, 2018–2027 (USD MILLION)
TABLE 8 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY SOFTWARE & SERVICES, 2018–2027 (USD MILLION)
TABLE 9 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)
TABLE 10 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY IMMUNOASSAY/IMMUNOCHEMISTRY, 2018–2027 (USD MILLION)
TABLE 11 INDONESIA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 12 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY CLINICAL CHEMISTRY, 2018–2027 (USD MILLION)
TABLE 13 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY MOLECULAR DIAGNOSTICS, 2018–2027 (USD MILLION)
TABLE 14 INDONESIA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 15 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HEMOSTASIS, 2018–2027 (USD MILLION)
TABLE 16 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HEMATOLOGY, 2018–2027 (USD MILLION)
TABLE 17 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY OTHERS, 2018–2027 (USD MILLION)
TABLE 18 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 19 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2018–2027 (USD MILLION)
TABLE 20 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DIABETES, 2018–2027 (USD MILLION)
TABLE 21 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DIABETES, 2018–2027 (USD MILLION)
TABLE 22 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY CARDIOLOGY, 2018–2027 (USD MILLION)
TABLE 23 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY AUTOIMMUNE DISEASES, 2018–2027 (USD MILLION)
TABLE 24 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HIV/AIDS, 2018–2027 (USD MILLION)
TABLE 25 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DRUG TESTING, 2018–2027 (USD MILLION)
TABLE 26 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY NEPHROLOGY, 2018–2027 (USD MILLION)
TABLE 27 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PHARMACOGENOMICS, 2018–2027 (USD MILLION)
TABLE 28 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY OTHERS, 2018–2027 (USD MILLION)
TABLE 29 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 30 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HOSPITALS, 2018–2027 (USD MILLION)
TABLE 31 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY LABORATORIES, 2018–2027 (USD MILLION)
TABLE 32 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY POINT-OF-CARE TESTING, 2018–2027 (USD MILLION)
TABLE 33 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY ACADEMIC INSTITUTES, 2018–2027 (USD MILLION)
TABLE 34 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY OTHERS, 2018–2027 (USD MILLION)
TABLE 35 MAJOR PLAYERS IN THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
TABLE 36 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
TABLE 37 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 38 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 39 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 40 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED
TABLE 41 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
TABLE 42 SIEMENS: PRODUCTS/SERVICES OFFERED
TABLE 43 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 44 QIAGEN: PRODUCTS/SERVICES OFFERED
TABLE 45 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES OFFERED

FIGURE 1 MARKET SYNOPSIS 11
FIGURE 2 MARKET STRUCTURE: INDONESIA IN-VITRO DIAGNOSTICS MARKET 12
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 19
FIGURE 4 MARKET DYNAMICS: INDONESIA IN-VITRO DIAGNOSTICS MARKET 22
FIGURE 5 VALUE CHAIN ANALYSIS: INDONESIA IN-VITRO DIAGNOSTICS MARKET 27
FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: INDONESIA IN-VITRO DIAGNOSTICS MARKET 29
FIGURE 7 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2020 & 2027 (USD MILLION) 32
FIGURE 8 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 & 2027 (USD MILLION) 35
FIGURE 9 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 41
FIGURE 10 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020 & 2027 (USD MILLION) 45
FIGURE 11 BENCHMARKING OF MAJOR COMPETITORS 49
FIGURE 12 REVENUE OF MAJOR PLAYERS, 2020 50
FIGURE 13 MAJOR PLAYERS R&D EXPENDITURE, 2020 50
FIGURE 14 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 52
FIGURE 15 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 53
FIGURE 16 SYSMEX CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 55
FIGURE 17 DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 58
FIGURE 18 DANAHER CORPORATION: SWOT ANALYSIS 59
FIGURE 19 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 61
FIGURE 20 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 62
FIGURE 21 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 64
FIGURE 22 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 67
FIGURE 23 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS 68
FIGURE 24 SIEMENS: FINANCIAL OVERVIEW SNAPSHOT 70
FIGURE 25 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 73
FIGURE 26 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 74
FIGURE 27 QIAGEN: FINANCIAL OVERVIEW 76
FIGURE 28 AGILENT TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT 79


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com